Gene therapy: the end of the rainbow?
Open Access
- 30 March 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Head & Neck Oncology
- Vol. 1 (1), 7-5
- https://doi.org/10.1186/1758-3284-1-7
Abstract
The increased understanding of the molecular basis of oral cancer has led to expectations that correction of the genetic defects will lead to improved treatments. Nevertheless, the first clinical trials for gene therapy of oral cancer occurred 20 years ago, and routine treatment is still not available. The major difficulty is that genes are usually delivered by virus vectors whose effects are weak and temporary. Viruses that replicate would be better, and the field includes many approaches in that direction. If any of these are effective in patients, then gene therapy will become available in the next few years. Without significant advances, however, the treatment of oral cancer by gene therapy will remain as remote as the legendary pot of gold at the end of the rainbow.Keywords
This publication has 48 references indexed in Scilit:
- Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancerCancer Gene Therapy, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1JCI Insight, 2008
- Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in TumorsCancer Research, 2008
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences, 2006
- Enhancement of antitumor activity of herpes simplex virus γ134.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamideCancer Gene Therapy, 2006
- Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus VectorCancer Research, 2006
- Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207)The FASEB Journal, 2004
- Intratumoral Spread of Wild-Type Adenovirus Is Limited After Local Injection of Human Xenograft Tumors: Virus Persists and Spreads Systemically at Late Time PointsHuman Gene Therapy, 2003
- Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating FactorMolecular Therapy, 2000
- US gene therapy in crisisTrends in Genetics, 2000